Nuvation Bio Inc.
NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor gā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.73
Price-5.78%
-$0.29
1Y
Price
Market Cap
$1.617b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1212.2%
EBITDA Margin-1220.9%
Net Profit Margin-
Free Cash Flow MarginRevenue
$14.355m
+82.3%
1y CAGR+27.4%
3y CAGR+20.6%
5y CAGREarnings
-$202.898m
+64.3%
1y CAGR-185.9%
3y CAGR-144.4%
5y CAGREPS
-$0.63
+70.1%
1y CAGR-135.2%
3y CAGR-103.7%
5y CAGRBook Value
$372.907m
$647.225m
Assets$274.318m
Liabilities$203.367m
DebtDebt to Assets
31.4%
-1x
Debt to EBITDAFree Cash Flow
-$120.221m
+7.9%
1y CAGR-18.1%
3y CAGR-23.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company